Ajanta Pharma: A Brand Profile

There is a habit in this corner of consumer goods journalism of writing about brands as if they materialised from marketing decks. They did not. Behind almost every intimate-care product on a European shelf sits a corporate parent with a registered office, an auditor, and a quarterly filing. Ajanta Pharma is one of the more legible examples, and it is worth spending a proper hour on because it clarifies how the pharmaceutical and adult categories overlap without necessarily colluding.

Ajanta Pharma Limited is a Mumbai-listed generics house with a long history in dermatology, cardiology and ophthalmology. It is publicly traded on the BSE and NSE. Its annual reports read like any mid-cap pharma — export markets across Africa and Asia, WHO-GMP certified plants, a research pipeline that is more workmanlike than headline-grabbing. None of this is scandalous, and none of it makes Ajanta an “adult” company in any meaningful sense. But its name comes up in conversations with European buyers often enough that a serious profile is overdue.

The corporate frame

The company was founded in 1973 and remains substantially family-controlled through the Agrawal family, which continues to feature prominently in its board disclosures. Its manufacturing is concentrated across a handful of Indian sites, with a footprint that reaches into Mauritius and, more recently, a US facility that turned Ajanta into a modest player in the American generics market. The revenue mix leans heavily on branded generics — the classic Indian pharma playbook of taking off-patent molecules and dressing them for specific therapeutic segments.

What matters for our beat is the erectile-dysfunction segment. Ajanta has, at various points in its public history, produced sildenafil citrate under a range of brand names for export markets. Some of those brand names — Kamagra being the most familiar — have travelled far beyond the pharmacies they were designed for. They now circulate in a grey channel of online sellers, unlicensed shops and back-of-the-counter arrangements across Europe. That is a distribution failure, not a manufacturing scandal, and it is important to keep the distinction sharp.

Where the intimate-care aisle enters

Ask a Balkan retailer what actually moves and the answer is unfailingly boring: condoms, water-based lubricant, a modest range of enhancement products. Look at eroticshop.me or any comparable regional operator and you will see the same lineup a Boots or DM would carry, plus a few categories a high-street chemist declines to stock. The Ajanta name does not typically appear on those shelves in Europe under its own label. What appears instead are parallel-import versions of the export brands, sourced through wholesalers whose paperwork is not always something a compliance officer would care to review.

I have spent enough time in retailer back-offices to know that most operators would rather stock a boring, licensed generic than a lively grey-market SKU. The problem is that the lively grey-market SKU has brand equity among buyers who searched for it long before they walked into a shop. This is where reputable retailers do actual work: they carry the licensed alternatives, they refuse the sketchy wholesaler, and they let a specialist prescriber handle anything requiring a script. A trusted online source that clearly separates the wellness aisle from the medicinal one is doing the customer a favour, even if it costs a few impulse sales.

The pharma-to-adult adjacency, in general terms

Ajanta is not the only pharma house whose exports end up adjacent to the adult category. Cipla, Sun and a long tail of smaller Gujarati and Maharashtrian manufacturers all produce SKUs that some downstream reseller decides to file under “lifestyle”. The category adjacency is structural: sildenafil and tadalafil are off-patent, cheap to manufacture, and demand is inelastic. Where legal pharmacy channels are inconvenient — because of cost, embarrassment, or genuine access barriers — a parallel market fills in.

None of this is a moral indictment of the manufacturers. Ajanta files with regulators, ships against orders, and does not, so far as any credible public record shows, court the grey channel. The problem sits at the reseller layer, and the fix sits with retailers willing to enforce a clean line. When I look at how the specijalizovana prodavnica model has evolved in the last five years across the Balkans, the better operators have professionalised — proper suppliers, invoices, VAT numbers, actual customer service — precisely because the shady end of the market is now competing with proper e-commerce discipline.

What a serious buyer notices

If you were procuring for a retail chain, three things about Ajanta would matter. First: does the specific SKU you are being offered carry proper import documentation for your jurisdiction? Second: is the wholesaler you are buying from actually authorised, or are they routing through a Cyprus or UAE shell? Third: does the packaging match the pharmacopoeia standards for the destination market, or is it in the export-only format that some regulators will not accept? A yes-yes-yes on those questions and Ajanta is as legitimate a supplier as any generics house. A no on any of them and the problem is with your intermediary, not the manufacturer.

I have watched retailers in Belgrade and Podgorica quietly walk away from otherwise attractive margins because the paperwork did not tie out. The ones who did that are still trading; the ones who did not are mostly gone. Anyone browsing kompletan katalog is, whether they know it or not, benefitting from the discipline of that first group.

The wider point

Ajanta Pharma is a useful case study because it dissolves the tidy fiction that “pharma” and “adult” are separate industries. They are not. They share molecules, they share manufacturing capacity, and at the reseller edge they occasionally share shelf space. The interesting question is not whether that adjacency should exist — it exists whether we approve or not — but whether the retail layer is honest about what it is selling and how it got there. On that question Ajanta itself has little to answer for. The distributors and resellers who ride its brand equity have rather more.

For readers who want to see how a competent regional operator handles this line in practice, the assortment at https://eroticshop.me/ is a reasonable working example — mainstream wellness in the front, the specialist categories properly labelled, and no attempt to blur the medicinal boundary. That is what a mature market looks like, and it is where the story of a company like Ajanta stops being a scandal and becomes, simply, a supply chain.